Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Revance Therapeutics Inc (RVNC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9998
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fasciitis among others. It also provides RT001, a topical gel formulation of daxibotulinumtoxinA, which is designed to eliminate the use of needles. Revance Therapeutics develops products for multiple aesthetic and therapeutic applications. The company utilizes TransMTS platform technology for the development of its products. It offers products for dermatology, neurology, musculoskeletal disorders, urology and ophthalmology. Revance Therapeutics is headquartered in Newark, California, the US.

Revance Therapeutics Inc (RVNC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Venture Financing 13
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Licensing Agreements 16
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Equity Offering 17
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc – Key Competitors 28
Revance Therapeutics Inc – Key Employees 29
Revance Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2018: Revance releases third quarter 2018 results 31
Aug 02, 2018: Revance releases second quarter 2018 results 33
May 08, 2018: Revance Releases First Quarter 2018 Results 34
Feb 28, 2018: Revance Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 02, 2017: Revance Releases Third Quarter 2017 Results 36
Aug 03, 2017: Revance Releases Second Quarter 2017 Results 37
May 09, 2017: Revance Releases First Quarter 2017 Results 38
Feb 27, 2017: Revance Releases Fourth Quarter and Full Year 2016 Results 39
Corporate Communications 41
Oct 11, 2018: Revance Therapeutics appoints Tobin C. Schilke as chief financial officer 41
May 09, 2018: Revance Therapeutics Announces Two Recent Additions to Its Management Team 42
May 01, 2018: Revance Therapeutics Appoints Caryn McDowell As SVP, General Counsel & Corporate Secretary 43
Sep 06, 2017: Revance Appoints Mark Foley to its Board of Directors 44
Aug 01, 2017: Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics 45
Product News 46
01/12/2017: Revance Therapeutics Enters into $6.4M Settlement with City of Warren Police and Fire Retirement System 46
Clinical Trials 47
Jun 05, 2017: Revance Reports Additional Positive Week 24 Efficacy Results from RT002 Injectable Phase 2 Cervical Dystonia Trial 47
May 18, 2017: Revance Announces Positive Top-Line 24-Week Duration of Effect Results in All Three Cohorts in RT002 Injectable Phase 2 Cervical Dystonia Trial 49
May 01, 2017: Revance Provides Update on Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis 51
Mar 07, 2017: Revance Completes Enrollment in Phase 3 Pivotal Trials of RT002 Injectable for the Treatment of Glabellar (Frown) Lines 52
Mar 03, 2017: Revance Announces BELMONT Phase 2 Clinical Data to Be Presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting 53
Jan 26, 2017: BELMONT Phase 2 Clinical Data to be Presented at IMCAS World Congress 2017 54
Jan 18, 2017: Revance Presents Clinical Data for RT002 Injectable at TOXINS 2017 55
Jan 05, 2017: Revance Provides Clinical Milestones and Financial Outlook for 2017 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Revance Therapeutics Acquires Intellectual Property Portfolio of Botulinum Toxin from Botulinum Toxin Research Associates 12
Revance Therapeutics Raises US$10 Million In Venture Financing 13
Revance Therapeutics Raises US$56 Million In Extended Series E Financing 14
Mylan Enters into Licensing Agreement with Revance Therapeutics 16
Revance Therapeutics Plans to Raise upto USD125 Million in Public Offering of Shares 17
Revance Therapeutics Raises USD167.1 Million in Public Offering of Shares 18
Revance Therapeutics Raises USD10.1 Million in Public Offering of Shares 20
Revance Therapeutics Raises USD134.6 Public Offering of Shares 21
Revance Therapeutics Raises USD10.8 Million in Public Offering of Shares 23
Revance Therapeutics Raises USD140.3 Million in Public Offering of Shares 24
Revance Therapeutics Completes IPO For US$110.4 Million 26
Revance Therapeutics Inc, Key Competitors 28
Revance Therapeutics Inc, Key Employees 29
Revance Therapeutics Inc, Subsidiaries 30

List of Figures
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Revance Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Revance Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nanobiotix SA (NANO):企業の財務・戦略的SWOT分析
    Summary Nanobiotix SA (Nanobiotix) is a late stage clinical company which develops nanomedicines for the treatment of cancers. The company develops first-in-class products utilizing its proprietary technology NanoXray, based on the physical mode of action of nanoparticles that increase the X-rays do …
  • Nuclear Decommissioning Authority:企業の戦略的SWOT分析
    Nuclear Decommissioning Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • West Pharmaceutical Services Inc (WST)-医療機器分野:企業M&A・提携分析
    Summary West Pharmaceutical Services Inc (West Pharmaceutical) manufactures components and systems for packaging and delivery of injectable drugs and delivery system components for use healthcare, pharmaceuticals and consumer product industries. Its product and services include stoppers and seals fo …
  • Columbus Life Insurance Company:企業の戦略的SWOT分析
    Columbus Life Insurance Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Hang Seng Bank Ltd:企業の戦略・SWOT・財務分析
    Hang Seng Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Hang Seng Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Actelion Ltd:企業の戦略・SWOT・財務分析
    Actelion Ltd - Strategy, SWOT and Corporate Finance Report Summary Actelion Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Orchard Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Orchard Therapeutics Ltd (Orchard) is an integrated commercial-stage biotechnology company that develops gene therapies for the treatment of serious and life-threatening orphan diseases. Its pipeline products include Strimvelis, an autologous ex vivo gammaretroviral gene therapy for the trea …
  • Boryung Pharmaceutical Co Ltd (003850):企業の財務・戦略的SWOT分析
    Summary Boryung Pharmaceutical Co Ltd (Boryung), formerly Boryung Drugs Co Ltd is a pharmaceutical company that develops drugs for the treatment of cancer, infections and gene therapy, besides vaccines, other biopharmaceuticals and new chemical entities (NCE). The company provides major products suc …
  • Estee Lauder Companies Inc:戦略・SWOT・企業財務分析
    Estee Lauder Companies Inc - Strategy, SWOT and Corporate Finance Report Summary Estee Lauder Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Trovagene Inc (TROV):医療機器:M&Aディール及び事業提携情報
    Summary Trovagene Inc (Trovagene) is a clinical-stage cancer therapeutics company that focuses on improved cancer care using its technology in tumor genomics. Its lead product, PCM-075, is a polo-like kinase 1 (PLK1) inhibitor that helps treat solid tumor cancers and multiple hematologic malignancie …
  • Keihan Holdings Co Ltd:企業の戦略・SWOT・財務分析
    Keihan Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Keihan Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Great Plains Energy Incorporated:企業の戦略・SWOT・財務情報
    Great Plains Energy Incorporated - Strategy, SWOT and Corporate Finance Report Summary Great Plains Energy Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • China Everbright Ltd (165):企業の財務・戦略的SWOT分析
    China Everbright Ltd (165) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Daniel Thwaites Plc:企業の戦略・SWOT・財務情報
    Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report Summary Daniel Thwaites Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Colabor Group Inc (GCL):企業の財務・戦略的SWOT分析
    Colabor Group Inc (GCL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Midatech Pharma Plc (MTPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Midatech Pharma Plc (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company’s products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimm …
  • Pharmaniaga Berhad (PHARMA):企業の財務・戦略的SWOT分析
    Pharmaniaga Berhad (PHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Enmax Corporation:電力:M&Aディール及び事業提携情報
    Summary ENMAX Corporation (ENMAX), a subsidiary of City of Calgary, is a vertically integrated energy utility. It generates, transmits and distributes electricity; supplies natural gas; and provides value-added services. Through its subsidiaries, the company undertakes deregulated electricity genera …
  • The Second Cup Ltd.:戦略・SWOT・企業財務分析
    The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Caltex Australia Ltd (CTX):企業の財務・戦略的SWOT分析
    Caltex Australia Ltd (CTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆